Advanced search
Publication Cover
Clinical and Experimental Gastroenterology Volume 10, 2017 - Issue
Submit an article Journal homepage
73
Views
8
CrossRef citations to date
0
Altmetric
Review

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis

Robin J Dart1 Department of Gastroenterology, IBD Centre, St. Thomas’ Hospital;2 Immunosurveillance Laboratory, The Francis Crick Institute, London;3 Division of Immunology, Infection, and Inflammatory Disease (DIIID), King’s College London
,
Mark A Samaan1 Department of Gastroenterology, IBD Centre, St. Thomas’ Hospital
,
Nick Powell1 Department of Gastroenterology, IBD Centre, St. Thomas’ Hospital;4 Department of Experimental Immunobiology, Division of Transplantation and Mucosal Biology, King’s College London, London, UK
&
Peter M Irving1 Department of Gastroenterology, IBD Centre, St. Thomas’ HospitalCorrespondence[email protected]
Pages 57-66 | Published online: 03 Mar 2017

Figures & data

Figure 1 Clinical effectiveness studies of vedolizumab in ulcerative colitis.

Notes: *At week 14, **data not available for steroid-free remission.
Figure 1 Clinical effectiveness studies of vedolizumab in ulcerative colitis.
 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.